AbCellera Plans 2027 Late-Stage Development for ABCL635

AbCellera Biologics Inc. plans to move its menopause hot-flash candidate ABCL635 into late-stage development in 2027 after a Phase 2 study found a reduction in moderate-to-severe episodes among participants who received the drug.

The study enrolled 92 postmenopausal women. At week four, women given a single subcutaneous 600-milligram dose had an average reduction of 8.8 hot flashes per day from baseline, compared with 3.5 per day in the placebo group. The placebo-adjusted difference was 5.3 events per day.

AbCellera expects to release 12-week and open-label extension data in early 2027. It also expects to start clinical trials in 2027 for vasomotor symptoms caused by hormone suppression associated with breast or prostate cancer treatment.

As of Sept. 30, the company listed more than $790 million in cash balances and marketable securities and more than $100 million in available government funding, for total available liquidity above $890 million. Based on its current business plan, AbCellera believes that liquidity can cover working capital and capital expenditures for at least 36 months following the date of the report. The measure includes government contributions, some of which are reimbursement-based and cannot be used for general corporate purposes.

The plans accompanied AbCellera's Q3 update and quarterly results showing $10.6 million in revenue and a $0.13 net loss per share.